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Introduction: This review investigates the role of p16INK4a as a 
marker of transcriptionally active human papillomavirus (HPV) in 
esophageal squamous cell carcinoma (ESCC) and the regional preva-
lence of HPV in ESCC.
Methods: PubMed, EMBASE, and the Cochrane Library were 
systematically searched with the purpose of identifying all stud-
ies published between January 1980 and July 2013 reporting both 
HPV and p16INK4a results in a minimum of five human ESCC 
specimens.
Results: Twelve studies were identified, providing data on a total of 
1383 ESCC specimens collected between 1987 and 2009 from 10 
different countries. HPV DNA was detected in 12.0% (n = 161) of 
1347 specimens, and p16INK4a was detected in 33.9% (n = 209) of 
617 specimens. The HPV presence varied from 0% to 70% among 
the studies. The prevalence of p16INK4a overexpression in HPV-
positive and HPV-negative specimens demonstrated no statistically 
significant difference, neither for the combined data (p = 0.7507) 
nor for any individual study, and detection of p16INK4a overexpres-
sion did not affect the odds of tumors being HPV positive (odds 
ratio = 1.0666 with 95% confidence interval 0.7040–1.6157). In 
a pooled analysis, the sensitivity of p16INK4a overexpression as a 
marker of HPV DNA presence was 0.35, the specificity 0.67, and 
the positive predictive value 0.25.
Conclusions: This systematic review reports great regional variation 
in the prevalence of HPV in ESCC and suggests that p16INK4a is not a 
reliable marker of HPV status in ESCC.
Key Words: Human papillomavirus, p16INK4a, Esophageal squamous 
cell carcinoma
(J Thorac Oncol. 2014;9: 865–871)
Human papillomavirus (HPV) is an established etiologic factor in cervical cancer1 and has been identified as a risk 
factor in oropharyngeal squamous cell carcinoma (SCC) as 
well.2 The rationale for establishing new causal links between 
specific cancers and HPV has been substantiated by the intro-
duction of preventive vaccines against HPV and by findings 
that HPV status in oropharyngeal cancer is associated with 
improved prognosis3 and changes in patient risk stratification.4
It seems plausible that the squamous epithelium of the 
esophagus could be exposed to HPV in the same manner as 
the oropharynx. Esophageal cancer is the eighth most com-
mon cancer worldwide and ranks as the world’s sixth lead-
ing cause of cancerous death.4 The involvement of the most 
common subtype, esophageal SCC (ESCC),5 with HPV has 
been investigated ever since the relationship was hypothesized 
by Syrjänen6 in 1982. So far, however, the data on the matter 
remain inconclusive.7 Results from in vitro studies and studies 
in bovine animals render an etiologic association likely,6 but 
population-based studies using various HPV detection meth-
ods report conflicting results, with HPV prevalence ranging 
from 0% to 60% to 70%6 and showing great regional varia-
tion.7 HPV detection rates are up to 500 times higher in areas 
with high ESCC incidence per year (so-called high risk areas) 
than in areas with low ESCC incidence per year.6 Evidence 
suggests that smoking and alcohol overuse and some physi-
cal factors and occupational exposures increase the risk of 
ESCC development,5 and it has been suggested that different 
etiologies of ESCC might explain the geographic divergence 
of HPV prevalence in ESCC.6
Many biomarkers of HPV and associated malignancies 
exist, including expressed oncoproteins, serologic markers, 
and direct detection of HPV DNA.8 Detection of HPV alone, 
however, leaves the risk of ascribing false clinical signifi-
cance to HPV which has not induced malignant transforma-
tion in cells. Including immunohistochemistry (IHC) for the 
tumor suppressor protein p16INK4a is a way of circumventing 
this problem.9 When transcriptionally active HPV is pres-
ent, hypophosphorylated retinoblastoma protein (pRb) binds 
to the HPV oncoprotein E7, allowing the transcriptional 
activator E2F to be constitutionally active while effectively 
stopping the negative feedback of free pRb on p16INK4a.10 
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Overexpression of p16INK4a ensues. It is possible for over-
expression of p16INK4a to be caused by molecular alterations 
independent from HPV infection. However, in oropharyngeal 
SCC, staining in greater than 50%, or better yet greater than 
75%, of cells has been found to correlate with the presence of 
transcriptionally active HPV.9
IHC for p16INK4a overexpression has been used as a surro-
gate marker of transcriptionally active HPV in both cervical11 
and oropharyngeal9 studies. The marker is generally acces-
sible, easily interpreted, and its technical costs are estimated 
to be two to 16 times lower than other HPV-specific tests.9 
As of yet, the possible role for p16INK4a as a surrogate marker 
of transcriptionally active HPV in ESCC has not been fully 
characterized. This literature review seeks to present the asso-
ciation between p16INK4a and HPV DNA in ESCC and provide 
insight into the etiologic role of HPV in ESCC carcinogenesis.
MATERIALS AND METHODS
Literature Search
In July 2013, one author (S.H.M.) systematically 
searched PubMed, EMBASE, and the Cochrane Library. In 
all libraries, “esophagus” along with “human papillomavirus” 
and “p16” was searched, including relevant synonyms and 
Medical Subject Headings (MeSH)  terms. Studies published 
between January 1980 and July 2013 reporting both HPV and 
p16INK4a results in a minimum of five human ESCC specimens 
were included. We had no restrictions regarding age, gender, 
or ethnicity.
Data Extraction
One author (S.H.) extracted data on HPV status, 
HPV detection method (polymerase chain reaction [PCR] 
or in situ hybridization [ISH]), p16INK4a status, definition of 
p16INK4a overexpression, geographic ESCC risk, and clini-
copathologic features. p16INK4a-positive specimens were 
grouped according to the percentage of staining used to 
define p16INK4a overexpression. For analysis of clinicopatho-
logic parameters, specimens were dichotomized between 
areas with high ESCC incidence per year and areas with low 
and medium incidence per year, according to how the area 
was defined in each study. The high incidence group solely 
includes studies characterizing themselves as being from 
high ESCC incidence areas.12–15 The low and medium group 
includes all studies characterizing themselves as being from 
areas of low or medium ESCC incidence, and three stud-
ies16–18 that lack information on geographic ESCC incidence. 
These three have been included in the low-medium group 
because among them, according to the IARC GLOBOCAN 
2008 database, the highest age standardized geographical 
esophageal cancer (i.e., both SCC and adenocarcinoma) inci-
dence for both sexes in 2008 was 5.9 per 100,000 (Pakistan). 
In comparison, the average age standardized incidence for 
both sexes in China in 2008 (a high risk country) was 16.7 
per 100,000. The fact that adenocarcinomas are included in 
the GLOBOCAN figures should not affect the ESCC risk 
assessment, as the GLOCOCAN figures place all three coun-
tries in the low-medium group.
Statistical Analysis
Fischer’s exact test was used to evaluate the association 
between HPV status and individual clinicopathologic factors. 
The student’s t test was used for the comparison of age means 
and consequently could be based only on the six studies pro-
viding information on standard deviation. Tumor differen-
tiation was analyzed by the χ2 test. The association between 
p16INK4a overexpression and HPV presence was analyzed by 
Fischer’s exact test for the eight studies providing p16INK4a 
data on both HPV-positive and HPV-negative specimens. The 
pooled data on this association were furthermore expressed as 
an odds ratio (OR), and the sensitivity, specificity, and positive 
predictive value (PPV) was calculated, each with a 95% confi-
dence interval (CI). All p values presented were two-sided and 
values of less than 0.05 were considered statistically signifi-
cant. Analyses were conducted using the statistical calculators 
on http://www.vassarstats.net, http://www.langsrud.com/stat/
fisher.htm, and http://www.medcalc.org/calc/odds_ratio.php.
RESULTS
Twelve studies (n = 1383) published between 2006 and 
2012 were included (Fig. 1), with specimens collected between 
1987 and 2009 from 10 different countries. 97.4% (n = 1347) 
of specimens were examined for HPV. Of these, 90.5% 
(n = 1219) were tested solely by PCR, 3.9% (n = 52) solely 
by ISH, and 5.6% (n = 76) by both ISH and PCR. HPV posi-
tivity varied from 0%19,20 to 70%.18 In total, 12.0% (n = 161) 
of the HPV-examined specimens tested HPV positive. The 12 
studies investigated the presence of between one and 37 HPV 
genotypes, resulting in 233 positive results spread over 29 
genotypes. Accordingly, some of the 161 HPV-positive speci-
mens were infected by multiple HPVs. HPV16 was the most 
prevalent type (45.1% of 233) followed by HPV18 (9.9% of 
233) and HPV52 (6.9% of 233).
Evaluation for p16INK4a was conducted in 44.6% (n = 617) 
of the specimens. Of these, 33.9% (n = 209) tested positive. 
Of the 766 specimens not analyzed for p16INK4a, 1.6% (n = 12) 
lacked material, whereas 98.4% (n = 754) were excluded 
 Excluded (n = 26) 
 14 were duplicates 
 3 had too few specimens 
 1 was an animal study 
 2 were cell immortalization studies
 6 were not about ESCC
Included
(n = 15)
Screening of full 
articles 
 Excluded (n = 3)   
 1 had no p16 data 
 2 had no experimental data
Included (n = 12)
Literature search: PubMed, EMBASE 
and The Cochrane Library
Search results combined (n = 41)
Articles screened on the 
basis of title and abstract
FIGURE 1.  Study selection
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because only HPV-positive specimens required p16INK4a evalu-
ation (Table 1). Six different definitions of p16INK4a overex-
pression were employed by the 12 studies: staining in 5% 
to 100% of cells,19 staining in 10% to 100% of cells,12,15,16,21 
staining in 40% to 100% of cells,18 staining in 50% to 100% 
of cells,23 a cervical or breast carcinoma/dysplasia specimen 
used as a positive control,14,20,22 or a verbal definition,13,17 e.g., 
“homogeneous staining of a clear majority of the tumor cells 
for p16 INK4a” (Table 2).
In total, eight studies (n = 543 specimens) provided data 
on p16INK4a status in both HPV-positive and HPV-negative 
specimens, hence the analysis of the HPV/p16INK4a association 
is based on these. We found that the prevalence of p16INK4a 
overexpression in HPV-positive and HPV-negative specimens 
showed no statistically significant difference, neither for the 
combined data (p = 0.7507) nor for any individual study 
(Table 3), and detection of p16INK4a overexpression did not 
affect the odds of tumors being HPV positive (OR = 1.0666 
with 95% CI 0.7040–1.6157; Table 4). In a pooled analy-
sis, the sensitivity of p16INK4a overexpression as a marker of 
HPV DNA presence was 0.35, the specificity 0.67, and the 
PPV 0.25 (Table 4).
Table 5 presents characteristics of specimens from areas 
with high geographic ESCC incidence per year versus areas 
with medium and low incidence per year. It demonstrates that 
there is no statistically significant association between regional 
ESCC incidence per year and HPV prevalence (p = 0.999). 
With regard to p16INK4a, it presents a statistically significant 
(p = 0.014) greater incidence per year of  p16INK4a-positive 
specimens in low-medium risk areas for ESCC incidence 
compared with high risk areas.
DISCUSSION
This review reports the association between p16INK4a 
and HPV DNA in ESCC. We found that p16INK4a is not a reli-
able marker of HPV status in ESCC because of low sensi-
tivity (0.35) and an OR which approximates 1 and overlaps 
the null value (OR = 1.0666, 95% CI 0.7040–1.6157). Also, 
we report highly divergent detection rates of HPV DNA with 
prevalences ranging from 1% to 65% within the same country 
and 0% to 70% between countries.
Within the 12 studies reviewed, the average detection rate 
of HPV was 12.0% overall, and 12.4% when pooling data only 
from studies using PCR detection. This percentage is com-
parable with the 15.2% HPV DNA detected by PCR in 2020 
ESCC specimens in a review by Syrjänen6 from 2002. When 
considering these averages, one should keep in mind that there 
is great disparity in the detected HPV prevalence among the 
studies. Between 0% and 70% of tumors contain HPV DNA, 
which is similar to the divergence found by Syrjänen6.
No support was found for using p16INK4a as a marker 
of transcriptionally active HPV in ESCC. The sensitivity 
of p16INK4a overexpression as a marker of HPV DNA was 
0.35 and the PPV 0.25. A statistically significant association 
between p16INK4a overexpression and HPV status could not 
be demonstrated (p = 0.7507), just as detection of p16INK4a 
overexpression did not affect the odds of tumors being HPV 
positive (OR = 1.0666, 95% CI 0.7040–1.6157). Although 
TABLE 1.  Detection of Human Papillomavirus (HPV) and p16INK4a in Esophageal Squamous Cell Carcinoma
Authors Country (Region)—ESCC Risk
HPV Detection 
Method HPV Types Detected HPV+ % p16INK4a+ %
Castillo et al.21 Columbia—LMR PCR HPV16, -18 16/47 34 25/46 54
Chile—LMR HPV16 5/26 19 12/26 46
Shuyama et al.15 China (Gansu) —HR PCR HPV6, -16, -18, -51 17/26 65 9/26 35
China (Shandong) —LMR HPV16, -18 2/33 6 10/33 30
Bellizzi et al.19 United States—LMR ISH — 0/29 0 23/31 74
Antonsson et al.22 Australia—LMR PCR HPV16, -35 8/222 4 4/8 50
Ding et al.12 China (Linzhou)—HR PCR HPV16 8/17 47 7/17 41
Koshiol et al.14 China (Linzhou) —HR PCR HPV16, -31, -89 3/267 1 0/3 0
Malik et al.20 Unite States—LMR ISH — 0/11 0 11/32 34
Castillo et al.16 Japan—LMR PCR HPV6, -16, -18, -51, -68 11/75 15 58/158 37
Pakistan—LMR HPV6, -16, -18, -35, -45 11/42 15
Columbia—LMR HPV6, -16, -18 9/49 18
Löfdahl et al.17 Sweden—LMR PCR HPV16, -33, -42, -45, -51, -52, -66, -82 20/204 10 22/130 17
Doxtader and 
Katzenstein23
United States—LMR ISH High risk subtype 1/12 8 6/20 30
Herbster et al.13 Brazil (south) —HR PCR and ISH HPV16, -18 19/84 23 10/64 16
Brazil (southeast)—LMR HPV16, -66 15/180 8
Vaiphei et al.18 India—LMR PCR HPV6, -11, -16, -18, -31, -33, -35, -39, 
-40, -42, -51, -52, -53, -54, -55, -59, 
-61, -66, -67, -68, -69, -73, -81, -82, 
-83, -CP6108, -IS39
16/23 70 12/23 52
Total 161/1347 12 209/617 34
ESCC, esophageal squamous cell carcinoma; LMR, low-medium risk; HR, high risk; PCR, polymerase chain reaction; ISH, in situ hybridization.
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only eight studies (543 specimens) contributed to this cor-
relation analysis, we deem it unlikely that the results are 
substantially biased by the lack of data from the remaining 
four studies, considering that none of these could reveal a 
significant association between p16INK4a overexpression and 
HPV status. The heterogeneous definitions of p16INK4a over-
expression constitute a definite uncertainty with regard to 
the pooled analysis. However, it is worth noting that out of 
all the reviewed studies, only one16 reported a statistically 
significant correlation between p16INK4a overexpression 
and HPV status (by the χ2 test, p = 0.036), and not only is 
this study included in the pooled correlation analysis, the 
reported association is also statistically insignificant by 
Fischer’s exact test (Table 3, p = 0.057).
Geographic distribution of ESCC has been identified as 
a common denominator for the discrepancies in HPV preva-
lence, and Syrjänen6 suggests that the divergent HPV detec-
tion rates might be explained by different etiologies of ESCC 
in high risk versus low risk areas. As alternative causes of 
ESCC, he cites risk factors such as nitrosamines, mycotox-
ins, cigarette smoke, alcohol and opium abuse, nutritional 
deficiencies, and physically damaging factors.6 Carcinogenic 
causes that are independent of HPV infection, however, do not 
necessarily explain why infection by a virus as globally wide-
spread as HPV might cause malignant transformation more 
readily in particular geographic areas. Gillison and Shah7 
call for identification of such cofactors. They list chronic 
thermal injury (caused by boiling water or hot maté in high 
incidence areas in China and Latin America), esophagitis, 
and dietary carcinogens as possible predisposing factors for 
HPV-related tumorigenesis. In the present review, a Brazilian 
study13 likewise speculates that the consumption of hot maté 
only in southern Brazil as opposed to in the southeast might 
explain the threefold difference between high risk southern 
and medium risk southeastern HPV prevalence (23% and 8%, 
respectively).
In this review, results from two of the studies12,14 
are inconsistent with the theorized etiologic heterogeneity 
between ESCC in high and low risk areas. These studies both 
use specimens from hospitals in the Chinese high risk region 
of Linzhou, but report HPV detection rates of 47% and 1% 
respectively. That is, conflicting results within the same high 
risk region. Based on discrepancies of this nature, the low 
prevalence study by Koshiol et al.14 goes on to question the 
veracity of the generally observed regional variation in HPV 
prevalence. They suggest that alternative explanations could 
include interlaboratory differences, low numbers of samples 
analyzed, different HPV detection assays, and false-positive 
HPV results because of contamination. Yet, applying this 
thinking to the studies in the present review does not satis-
factorily explain the detection of regional HPV variances in 
the studies from Brazil (south 23% and southeast 8%)13 and 
China (Gansu 65% and Shandong 6%),15 which use the same 
methodology for detecting HPV in both areas.
The hypothesis concerning the existence of a real 
geographic etiologic heterogeneity of HPV in ESCC is 
not supported by the material in this review. No statisti-
cally significant difference was detected between the HPV 
prevalence in regions with high (11.9% HPV) and low-
medium (12.0% HPV) ESCC incidence per year (Table 5, 
p = 0.999). It should be noted, though, that HPV prevalence 
rates were highly divergent within both groups, ranging 
from 0% to 70% in the low-medium incidence group and 
from 1% to 65% in the high incidence group. A tendency 
that could mask some geographic variation is that patients 
may not live in the same region as the hospital from 
which samples are collected. This is exemplified by the 
study by Koshiol et al.,14 because patients, although from 
the same hospital, came from 13 of the 31 provinces of 
China. Similarly, in studies where only convenient ESCC 
samples are used, as in the study by Shuyama et al,15 the 
TABLE 2.  Overview of Definitions of p16INK4a Overexpression
Definition of p16INK4a Overexpression
No. of  
Studies p16INK4a+ %
Staining in 5–100% of cells 1 23/31 74
Staining in 10–100% of cells 4 121/306 40
Staining in 40–100% of cells 1 12/23 52
Staining in 50–100% of cells 1 6/20 30
Cervical carcinoma/dysplasia control 3 15/43 35
Verbal definition 2 32/194 16
Total 12 209/617 34
TABLE 3.  Co-occurence of p16INK4a and All Types of Human Papillomavirus (HPVall)
Author Country (Region)
HPVall+  
and p16+
HPVall+  
and p16−
HPVall−  
and p16+
HPVall−  
and p16−
No. Double 
Pos. as % of 
HPVall+
No. Double 
Neg. as % of 
HPVall−
Fischer’s 
p Value
Castillo et al.21 Columbia, Chile 12 9 25 26 57% 51% 0.6088
Shuyama et al.15 China (Gansu and Shandong) 3 16 16 24 16% 60% 0.0791
Bellizzi et al.19 United States 0 0 23 8 0% 26% 0.9999
Ding et al.12 China (Linzhou) 2 6 5 4 25% 44% 0.3348
Castillo et al.16 Japan, Pakistan, Columbia 16 14 42 86 53% 67% 0.0568
Löfdahl et al.17 Sweden 4 13 18 95 24% 84% 0.4877
Doxtader and Katzenstein23 United States 1 0 5 6 100% 55% 0.9999
Herbster et al.13 Brazil (south and southeast) 7 27 3 27 21% 90% 0.3131
Total 543 specimens examined 45 (8%) 85 (16%) 137 (25%) 276 (51%) 45/130 (35%) 276/413 (67%) 0.7507
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ESCC specimens analyzed may not be representative of 
the ESCC cases in the study area. This caveat could apply 
to HPV studies in general.
In contrast to what was demonstrated regarding HPV 
status, a statistically significant difference was in fact detected 
for p16INK4a overexpression between the high risk and the 
 low-medium risk group for ESCC incidence per year: 36% 
(n = 507) of tumors from the low-medium risk group were 
p16INK4a positive whereas this was only the case for 24% 
(n = 110) of tumors from the high risk group (Table 5). If p16INK4a 
were considered a marker of transcriptionally active HPV, this 
finding would oppose the hypothesis of a greater role for tran-
scriptionally active HPV in the etiology of ESCC in areas at 
high risk for ESCC. However, p16INK4a overexpression could 
be caused by molecular alterations in the p16INK4a pathway that 
are not induced by HPV infection, and the question of whether 
such mechanisms are related to ESCC high risk regions is a 
possible area for future study. The significant result is biased 
by the exclusion of 55% of all tumor samples from the p16INK4a 
analysis and by the overrepresentation of HPV-positive speci-
mens (24% in this group versus the average of 12%) among 
the p16INK4a-analyzed specimens. Another notable uncertainty is 
constituted by the lack of uniformity in cutoff values for deter-
mining p16INK4a positivity among the studies.
It was not possible to statistically evaluate the associa-
tion between geographic ESCC incidence per year and the 
TABLE 4.  OR, Sensitivity, Specificity, and PPV
HPV+ HPV−
p16INK4a+ 45 137
p16INK4a− 85 276
OR 1.066 (95% CI 0.704–1.616)
Sensitivity 0.346 (95% CI 0.266–0.435)
Specificity 0.668 (95% CI 0.620–0.713)
PPV 0.247 (95% CI 0.188–0.318)
OR, odds ratio, PPV, positive predictive value; CI, confidence interval.
TABLE 5.  Clinicopathologic Features
Characteristic
Total High Geographic ESCC Incidence Low and Medium Geographic ESCC Incidence
p ValueNo. % No. % No. %
No. of specimens 1383 100 399 29 984 71
Sex 0.000
  Male 895 67 405 74 490 63
  Female 433 33 146 26 287 37
  Total 1328 100 551 100 777 100
Age (years) < 0.0001
  Mean 62.4 59.6 63.4
Tumor differentiation <0.0001
  Low 214 26 57 26 157 29
  Medium 286 39 26 12 260 48
  High 260 35 137* 62 123 23
  Total no. examined 760 100 220 100 540 100
p16INK4a status 0.014
  Positive 209 34 26 24 183 36
  Negative 408 66 84 76 324 64
  Total no. examined 617 100 110 100 507 100
HPV status 0.999
  Positive 161 12 47 12 114 12
  Negative 1186 88 347 88 839 88
  Total no. examined 1347 100 394 100 953 100
Smoking 0.931
  Never 201 26 132 26 69 26
  Ever 571 74 371 74 200 74
  Total no. examined 772 100 503 100 269 100
Alcohol consumption 0.000
  < 7 drinks/week 255 36 130 30 125 48
  Ever 445 64 309 70 136 52
  Total no. examined 700 100 439 100 261 100
Numbers not adding to 1383 specimens (100%) are due to missing data
*Of these, 131 were termed “well and moderately differentiated”.
ESCC, esophageal squamous cell carcinoma.
870 Copyright © 2014 by the International Association for the Study of Lung Cancer
Høxbroe et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014
combined HPV/p16INK4a status of each specimen, as the com-
bined HPV/p16INK4a data from two13,15 of the four high risk 
regions were pooled with the data from low and medium risk 
areas, leaving insufficient data for significant statistical analy-
sis. Likewise, our original intention was to examine whether 
the correlation between HPV positivity and p16INK4a positiv-
ity would change with the cutoff value used to define p16INK4a 
overexpression. The proposed groups were greater than 70% 
positivity (0 studies), greater than 50% positivity (one study), 
greater than 5% positivity (six studies), and a verbal defini-
tion/control specimen (five studies). However, the skewed 
distribution of specimens among these groups rendered sys-
tematic analysis impossible (Table 2) and it remains for future 
studies to investigate the consequence of this approach.
A proposed6,24 explanation for p16INK4a positivity in the 
absence of detectable HPV DNA is by the “hit and run” mech-
anism known from studies in bovine animals.25 Bovine papillo-
mavirus type 4 (BPV-4) causes a diffuse papillomatosis in the 
alimentary tract of cattle which is cleared by a  cell-mediated 
immune response unless the cattle ingest bracken fern. It has 
been shown that although BPV-4 is required for these early 
stages of carcinogenesis, the presence of the virus is not 
required for progression to the malignant state25—hence the 
“hit and run” designation. By analogy to HPV, this would 
mean that HPV could be responsible for the early steps of 
human esophageal carcinogenesis without remaining at 
detectable levels in ESCC. Even so, Gillison and Shah7 reason 
that the lack of an association between HPV L1 seroreactivity 
and ESCC and the little evidence of HPV presence in benign 
HPV papillomas argue against a “hit and run” mechanism in 
HPV-related esophageal carcinogenesis in Western cultures.
Silencing of p16INK4a is common in ESCC and could 
account for some of the p16INK4a-negative specimens with 
detectable HPV DNA. A study by Tokugawa et al.26 on 42 
ESCCs reported silencing of p16INK4a in as many as 90.5% 
of the specimens by either hypermethylation of the p16INK4a 
promotor or by deletion (loss of heterozygosity or homozy-
gous) at the near-p16INK4a loci and possible point mutation. 
Similarly, a Chinese study15 in the present review reported 
p16INK4a downregulation in 68% of ESCC specimens regard-
less of HPV status.
This review accentuates the heterogeneity of HPV in 
ESCC. The lack of consistency regarding geographic areas, 
cutoffs for p16INK4a positivity, and antibodies used makes com-
paring the studies problematic. Notwithstanding, the lack of 
support for using p16INK4a as a marker of HPV in ESCC was 
present in all studies, irrespective of HPV prevalence, and pro-
vides rationale for resisting the notion that p16INK4a should be 
a routine testing for ESCC. Rather, it should be reserved for 
large, controlled trials. Assuming that co-occurrence of HPV 
DNA and p16INK4a overexpression is indicative of HPV infec-
tion, this review suggests that HPV may have an etiologic role 
in merely 4.1% of ESCCs.
Regarding future work, standardization of biopsy sizes, 
staining conditions (regarding monoclonal antibody clones), 
and cutoff values for p16INK4a IHC would ease interpreta-
tion of data pooled from separate studies. More homoge-
neous methods would allow for examination of whether the 
 co-occurrence of p16INK4a and HPV DNA changes with the 
definition of p16INK4a overexpression.
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